Incyte Corporation

INCY Healthcare Biotechnology

Incyte Corporation’s revenue for fiscal 2025 (year ended December 2025) was $5.1 billion, up 21.2% from fiscal 2024. In the quarter to June 2026, revenue grew 37.7%, EPS grew 39.7%, free cash flow grew 1,829.5% and total debt fell 10.5%, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for ten consecutive years.

116.27 3.02 +2.67%
Market cap
$23.0B
P/E
13.9×
Fwd P/E
58.4×
Dividend yield
—
F-score
9/9
Altman Z
8.57
Beneish M
−2.43
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

13.86 14.97 12.89 13.94
P/S ratio
3.45 3.75 3.50 3.90
P/FCF ratio
14.16 14.50 13.20 12.02
P/Operating CF
29.67 35.49 50.80 44.74
P/B ratio
3.57 3.73 3.34 3.58
EV/Sales
2.85 3.06 2.76 3.13
EV/EBITDA
8.72 9.79 8.67 9.71
EV/FCF
11.70 11.84 10.41 9.64
Current Ratio
3.20 3.32 3.68 4.59
Net Debt/EBITDA
(6.20) (9.87) (12.27) (6.22)
Debt/Equity
0.01 0.01 0.01 0.00
Earnings Yield
7.22% 6.68% 7.76% 7.17%
Free Cash Flow Yield
7.06% 6.90% 7.57% 8.32%
Free Cash Flow per Share
2.66 2.67 1.78 2.47
Book value per Share
23.77 26.47 28.21 31.66
Free Cash Flow
519.64 521.42 354.15 495.25
EV/EBIT
9.26 10.39 9.18 10.24
Other line items

Show all line items

Columns are period end dates